Comparison Chart AnaptysBio, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 12:22:53 2024-05-21 pm EDT			5-day change	1st Jan Change
24.86 ^USD	-0.60%		-2.53%	+14.94%

May. 09	AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	ANAPTYSBIO, INC.	Bio Therapeutic Drugs	-1.56%	-2.53%	+14.94%	+23.22%	-65.16%	683M